Zmanindc, Of course that is the case as generic Lovasa is cheap, so why
pay for something much more expensive. This was a problem early on and
AMRN management never came up with a solution. So even many generic
Vascepa scrips get switched over to generic Lovasa. The FDA could care
less about the situation. Maybe if BP owned AMRN they would care a bit
more. At least in Europe this will not be a problem. Of course, in the
US if a BP were to rebrand Vascepa and point out the reasons why only
Branded Vascepa will result in the highest benefit and anything else
be it a generic or a DS may not have any health benefit and may actually
be detrimental to ones health. Then the message that has to be put
across is that the longer one takes Vascepa, the greater the health
benefits that may accrue from its use. The patient must understand
that it is the continuous use of branded Vascepa that will provide
the greatest protection against CVD including heart attack and stroke.
(I use to argue with JL about how educating doctors and patients would
be the most critical factor in Vascepa's success.) In that regard,
management of Amarin has failed. Perhaps Europe will turn out
different but I believe the only way to assure the highest uptake
of the drug if through a BP distribution network. This is all
common sense.
Market Data 
Markets 
AI
